Contact Details
| Organization: | Pharmacology, Medicine - Royal Melbourne and Western Hospitals |
| Position: | PROFESSOR, PROFESSOR |
| Email: | |
| Homepage: | http://www.medrmhwh.unimelb.edu.au/staff/academic/anderson.html |
| Work: | 8344 8602 |
| Fax: | 9347 1863 |
| Level: | 04 |
| Building: | Clinical Sciences |
| Campus: | Royal Melbourne Hospital |
Research Expertise and International Linkages
Research Expertise
| Research Interest | Key Words | Country of Expertise |
|---|---|---|
| Mechanisms and treatment of asthma, COPD (chronic obstructive lung disease), and other lung diseases | Australia | |
| Understanding how disease occurs by studying basic mechanisms in experimental models and in patients who volunteer for research | asthma, COPD, lung disease, treatments for lung disease | Australia |
Qualifications, Honours, Fellowships and Other Awards
Qualifications
| Title | Institution | Date Awarded | Abbreviation |
|---|---|---|---|
| Bachelor of Science | University of Melbourne | 01-Jan-1986 | |
| Doctor of Philosophy | University of Melbourne | 01-Jan-1990 |
Government Research Classifications
Research Fields, Courses and Discipline Classifications
- Cellular Interactions (incl. Adhesion, Matrix, Cell Wall) (BIOCHEMISTRY AND CELL BIOLOGY) (270105)
- Virology (MICROBIOLOGY) (270303)
- Gene Therapy (BIOTECHNOLOGY) (270801)
- Biotechnology not elsewhere classified (BIOTECHNOLOGY) (270899)
- Anatomy and Physiology (VETERINARY SCIENCES) (300505)
- Allergy (IMMUNOLOGY) (320201)
- Cellular Immunology (IMMUNOLOGY) (320202)
- Humoral Immunology and Immunochemistry (IMMUNOLOGY) (320203)
- Tumor Immunology (IMMUNOLOGY) (320206)
- Immunology not elsewhere classified (IMMUNOLOGY) (320299)
- Medical Biochemistry: Proteins and Peptides (MEDICAL BIOCHEMISTRY AND CLINICAL CHEMISTRY) (320305)
- Medical Virology (MEDICAL MICROBIOLOGY) (320402)
- Basic Pharmacology (PHARMACOLOGY AND PHARMACEUTICAL SCIENCES) (320502)
- Clinical Pharmacology and Therapeutics (PHARMACOLOGY AND PHARMACEUTICAL SCIENCES) (320503)
- Toxicology (incl. Clinical Toxicology) (PHARMACOLOGY AND PHARMACEUTICAL SCIENCES) (320504)
- Pharmacology not elsewhere classified (PHARMACOLOGY AND PHARMACEUTICAL SCIENCES) (320599)
- Cell Physiology (MEDICAL PHYSIOLOGY) (320602)
- Systems Physiology (MEDICAL PHYSIOLOGY) (320603)
- Central Nervous System (NEUROSCIENCES) (320702)
- Dental Therapy (DENTISTRY) (320804)
- Dermatology (CLINICAL SCIENCES) (321002)
- Infectious Diseases (CLINICAL SCIENCES) (321010)
- Neurology and Neuromuscular Diseases (CLINICAL SCIENCES) (321013)
- Oncology and Carcinogenesis (CLINICAL SCIENCES) (321015)
- Rehabilitation and Therapy: Occupational and Physical (CLINICAL SCIENCES) (321024)
- Respiratory Diseases (CLINICAL SCIENCES) (321027)
- Rheumatology and Arthritis (CLINICAL SCIENCES) (321028)
- Medical Biotechnology (OTHER MEDICAL AND HEALTH SCIENCES) (329902)
- Educational Policy, Administration and Management (EDUCATION STUDIES) (330104)
- Educational Technology and Media (EDUCATION STUDIES) (330107)
- Social Program Evaluation (SOCIAL WORK) (370202)
- Counselling, Welfare and Community Services (SOCIAL WORK) (370204)
Socio-Economic Objective Classifications
- Livestock not elsewhere classified (LIVESTOCK) (630199)
- Prevention - biologicals (e.g. vaccines) (HUMAN PHARMACEUTICAL PRODUCTS) (670401)
- Treatments (e.g. chemicals, anntibiotics) (HUMAN PHARMACEUTICAL PRODUCTS) (670403)
- Human pharmaceutical products (PREVENTION AND TREATMENT OF POLLUTION) (671704)
- Computer software and services not elsewhere classified (COMPUTER SOFTWARE AND SERVICES) (700199)
- Infectious diseases (CLINICAL; ORGANS, DISEASES AND ABNORMAL CONDITIONS) (730101)
- Immune system and allergy (CLINICAL; ORGANS, DISEASES AND ABNORMAL CONDITIONS) (730102)
- Nervous system and disorders (CLINICAL; ORGANS, DISEASES AND ABNORMAL CONDITIONS) (730104)
- Endocrine organs and diseases (incl. Diabetes) (CLINICAL; ORGANS, DISEASES AND ABNORMAL CONDITIONS) (730105)
- Cancer and related disorders (CLINICAL; ORGANS, DISEASES AND ABNORMAL CONDITIONS) (730108)
- Respiratory system and diseases (incl. Asthma) (CLINICAL; ORGANS, DISEASES AND ABNORMAL CONDITIONS) (730110)
- Oro-dental and disorders (CLINICAL; ORGANS, DISEASES AND ABNORMAL CONDITIONS) (730112)
- Skeletal system and disorders (incl. Arthritis) (CLINICAL; ORGANS, DISEASES AND ABNORMAL CONDITIONS) (730114)
- Skin and related disorders (CLINICAL; ORGANS, DISEASES AND ABNORMAL CONDITIONS) (730117)
- Organs, diseases & abnormal conditions not elsewhere classified (CLINICAL; ORGANS, DISEASES AND ABNORMAL CONDITIONS) (730118)
- Clin health not spec to partlar organs, diseases & condits (CLINICAL; ORGANS, DISEASES AND ABNORMAL CONDITIONS) (730199)
- Nursing (HEALTH AND SUPPORT SERVICES) (730302)
- Health and support services not elsewhere classified (HEALTH AND SUPPORT SERVICES) (730399)
- Higher education (HIGHER EDUCATION) (740301)
- Vocational education and training (VOCATIONAL EDUCATION AND TRAINING) (740401)
- Education policy (OTHER EDUCATION) (749906)
- Aboriginal & Torres Strait Islander development & welfare (COMMUNITY SERVICE EXCL. WORK) (750309)
- Biological sciences (NON-ORIENTED RESEARCH) (780105)
Grants and Contracts
Research Grants, Contracts and Consultancies awarded to the University of Melbourne as the administering institution (since 2003) as recorded in Themis Agreements.
Grants
| Title | Role | Funding Source | Scheme | Award Date |
|---|---|---|---|---|
| Therapeutic macrophages derived from ES cells to treat COPD | Principal Supervisor | GLAXOSMITHKLINE AUSTRALIA | GSK Post Graduate Support Grant | 03/02/2003 |
| Co-operative Research Centre for Chronic Inflammatory diseases -Program 3 | Chief Investigator | CRC FOR CHRONIC INFLAMMATORY DISEASES | Research Grant | 01/01/2005 |
| DEVELOPMENT OF A HIGHLY POTENT, FULLY HUMAN ANTI-GM-CSF MONOCLONAL ANTIBODY | Chief Investigator | NHMRC | Development Grants | 01/01/2005 |
| Self-Management Strategy, Microbial Infection Patterns and Bomarkers in Patients with Exacerbations of COPD | Principal Supervisor | NHMRC | Medical & Dental Postgraduate Scholarships | 01/01/2005 |
| FROM COLONISATION TO CONCILIATION: A COLLABORATIVE EXAMINATION OF SOCIAL WORK PRACTICE WITH INDIGENOUS POPULATIONS | Chief Investigator | ROYAL CHILDREN'S HOSPITAL FOUNDATION, MERCY HOSPITAL FOR WOMEN, AUST RESEARCH COUNCIL |
Linkage Projects (AUST RESEARCH COUNCIL) | 01/01/2005 |
| THE INTERFACE BETWEEN INNATE AND ADAPTIVE IMMUNITY | Chief Investigator | MONASH UNIVERSITY | Project Grants (NHMRC) | 01/01/2005 |
| INTRA-ARTICULAR MEDICATION AS RISK FACTOR FOR MUSCULOSKELETAL INJURY | Chief Investigator | UNIVERSITY OF MELBOURNE, RURAL INDUSTRIES R & D CORPORATION |
Project Grants (RURAL INDUSTRIES R & D CORPORATION) | 01/05/2007 |
| THE ROLE OF SRC FAMILY TYROSINE KINASES IN INFLAMMATORY LUNG DISEASE AND CANCER | Chief Investigator | LUDWIG INST CANCER RESEARCH | Project Grants (NHMRC) | 01/01/2008 |
| UTILITY OF POC PREDICTIVE BLOOD BIOMARKERS IN TRIAGE AND MANAGEMENT OF HIGH RISK POPULATIONS | Chief Investigator | NHMRC | H1N1 Influenza | 01/01/2009 |
Contracts
| Title | Role | Funding Source | Award Date |
|---|---|---|---|
| CHARACTERISATION OF AGENTS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | Chief Investigator | CERYLID BIOSCIENCES PTY LTD | 17/08/2004 |
| Co-operative Research Centre for Chronic Inflammatory diseases -Program 3 | Chief Investigator | CRC FOR CHRONIC INFLAMMATORY DISEASES | 01/01/2005 |
| TARGETING G-CSF IN EXPERIMENTAL LUNG INFLAMMATION MODELS RELEVANT TO COPD (CHRONIC OBSTRUCTIVE LUNG DISEASE) | Chief Investigator | AMRAD OPERATIONS PTY LTD, UNIVERSITY OF MELBOURNE |
01/09/2005 |
| CONSULTANCY AGREEMENT - METABOLIC TESTING NOVEL CONOTOXIN | Chief Investigator | METABOLIC PHARMACEUTICALS LTD | 01/09/2005 |
| THE EFFECT OF CIGARETTE SMOKE ON 12/15 LIPOXYENASE KNOCKOUT MICE | Chief Investigator | BIOLIPOX AB | 18/11/2005 |
| TARGETING G-CSF IN EXPERIMENTAL LUNG INFLAMMATION MODELS RELEVANT TO COPD (CHRONIC OBSTRUCTIVE LUNG DISEASE) | Chief Investigator | ZENYTH THERAPEUTICS LTD | 23/11/2006 |
| EVALUATION OF A TEST COMPUND FOR POTENTIAL INHIBITION OF VIRUS INDUCED EXACERBATIONS OF COPD IN MICE | Chief Investigator | PFIZER INC | 22/12/2006 |
| HSC AND MHC TRANSPLANTATION FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Chief Investigator | UNIVERSITY OF MELBOURNE, AUST STEM CELL CENTRE LTD (ASCC) |
29/10/2007 |
| ASSESSMENT OF NOVEL THERAPEUTIC AGENTS IN ANIMAL MODELS OF DISEASE | Chief Investigator | AUS BIO LIMITED | 18/02/2008 |
| THE EFFECT OF A POTENTIAL THERAPEUTIC AGENT ON OZONE CHALLENGED MICE | Chief Investigator | TOPIGEN PHARMACEUTICALS INC | 01/10/2008 |
| POTENTIALLY THERAPEUTIC AGONISTS IN COPD | Chief Investigator | ROCHE PALO ALTO LLC | 13/10/2008 |
| THE EFFECT OF POTENTIAL THERAPEUTICS INFLUENZA INFECTED MICE | Chief Investigator | RESPIVERT LTD | 16/04/2009 |
| THE EFFECTS OF NOVEL TEST AGENTS AND REFERENCE COMPOUNDS ON RSV INFECTED CELLS | Chief Investigator | RESPIVERT LTD | 06/05/2009 |
| THE EFFECT OF POTENTIAL THERAPEUTICS IN RSV INFECTED MICE | Chief Investigator | RESPIVERT LTD | 14/07/2009 |
| EFFECT OF RESPIRATORY SYNCYTIAL VIRUS ON AIRWAY HYPERRESPONSIVENESS | Chief Investigator | RESPIVERT LTD | 26/10/2009 |
Publications
Publications produced at the University of Melbourne and reported in the Annual Publications Collection and 'Research Report' since 2001. The Themis Publications module, released in November 2006, allows additional publications from previous institutions and publications from past years to be entered.